Search research articles

ACERCA DE JoVE

Visión General Liderazgo Blog Centro de Ayuda JoVE

AUTORES

Proceso de Publicación Consejo Editorial Alcance y Políticas Revisión por Pares Preguntas Frecuentes Enviar

BIBLIOTECARIOS

Testimonios Suscripciones Acceso Recursos Consejo Asesor de Bibliotecas Preguntas Frecuentes

INVESTIGACIÓN

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archivo

EDUCACIÓN

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Centro de Recursos para Profesores Sitio de Profesores

Términos y Condiciones de Uso

Política de Privacidad

Videos de Conceptos Relacionados

Antihypertensive Drugs: Potassium-Sparing Diuretics

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Heart Failure Drugs: Diuretics

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Heart Failure Drugs: β-Blockers

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...

Heart Failure V: Medical Management

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por

Same author

Adipose tissue as a site of immune activation and dysfunction in individuals with obesity and asthma.

bioRxiv : the preprint server for biology·2026

Same author

Modest Contribution of Bradykinin to Blood Pressure Reduction by Sacubitril/Valsartan in Chronic Heart Failure.

Circulation. Heart failure·2026

Same author

Risk of Coronary Artery Disease Associated With Transitions in Metabolic Health in a Clinical Cohort of 69 272.

Journal of the American Heart Association·2025

Same author

RISING STARS: Effects of a GLP-1 receptor polymorphism on responses to liraglutide.

The Journal of endocrinology·2025

Same author

Regional and systemic adipose mass and peripheral conduit artery function.

Diabetes research and clinical practice·2025

Same author

Increased formation of angiotensin II from angiotensin I in individuals of African descent.

Journal of hypertension·2025

Search research articles

Video Experimental Relacionado

Updated: Jul 4, 2026

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats

Published on: December 5, 2017

Eplerenona: Protección cardiovascular para la salud

Nancy J Brown¹

¹Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tenn 37232-6602, USA. nancy.j.brown@vanderbilt.edu

|May 21, 2003

Resumen

La aldosterona causa daño a los órganos, pero los bloqueadores no selectivos tienen efectos secundarios. Un nuevo bloqueador selectivo de la aldosterona, la eplerenona, es prometedor para el tratamiento de enfermedades cardiovasculares y renales con mayor seguridad.

Más Videos Relacionados

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Videos de Experimentos Relacionados

Last Updated: Jul 4, 2026

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats

Evaluation of Vascular Control Mechanisms Utilizing Video Microscopy of Isolated Resistance Arteries of Rats

Published on: December 5, 2017

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Área de la Ciencia:

Medicina cardiovascular La medicina cardiovascular es una especialidad de la medicina cardiovascular.
Nefrología Nefrología.
Endocrinología Endocrinología.

Sus antecedentes:

La aldosterona contribuye a la lesión cardiovascular y renal a través de los receptores de mineralocorticoides.
Los antagonistas no selectivos del receptor de aldosterona como la espironolactona tienen limitaciones debido a los efectos secundarios.

Objetivo del estudio:

Revisar la farmacología, eficacia y seguridad de la eplerenona, un antagonista selectivo del receptor de aldosterona.
Para discutir el papel de la aldosterona en la toxicidad cardiovascular y los beneficios del antagonismo selectivo.

Principales métodos:

Revisión de los datos existentes de estudios en animales y ensayos clínicos.
Evaluación farmacológica de la eplerenona.
Análisis de los perfiles de eficacia y seguridad.

Principales resultados:

La eplerenona es un antagonista selectivo del receptor de la aldosterona.
El antagonismo selectivo ofrece ventajas potenciales sobre los agentes no selectivos.
La evidencia emergente destaca el papel de la aldosterona en la toxicidad cardiovascular.

Conclusiones:

La eplerenona presenta una opción potencialmente más segura y efectiva para el manejo de las condiciones relacionadas con el exceso de aldosterona.
El antagonismo selectivo del receptor de aldosterona es una estrategia terapéutica prometedora para la protección cardiovascular y renal.